A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
NCT06827613
This study is recruiting at 6 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab Govitecan in Participants with Unresectable, Locally Advanced, or Metastatic Solid Tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Triple Negative Locally Advanced Non-resectable Breast Cancer
- HR+, HER2-, Advanced Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Marengo Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- September 24, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- UCLA Health · Los Angeles, CA
- USC Norris Comprehensive Cancer Center · Los Angeles, CA
Massachusetts · 1
- Massachusetts General Hospital Cancer Center · Boston, MA
Ohio · 1
- Ohio State University Comprehensive Cancer Center · Columbus, OH
Tennessee · 1
- Sarah Cannon Research Institute · Nashville, TN
Texas · 1
- UT Health San Antonio MD Anderson Cancer Center · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.